What is the current market valuation of the US chronic idiopathic-constipation market?

The market valuation was $1285.52 Million in 2024. Read More

What is the projected market size for the US chronic idiopathic-constipation market by 2035?

The projected market size is $2750.67 Million by 2035. Read More

What is the expected CAGR for the US chronic idiopathic-constipation market during the forecast period?

The expected CAGR is 7.16% from 2025 to 2035. Read More

Who are the key players in the US chronic idiopathic-constipation market?

Key players include AbbVie, Boehringer Ingelheim, Ironwood Pharmaceuticals, Takeda Pharmaceutical, AstraZeneca, Sucampo Pharmaceuticals, Salix Pharmaceuticals, and GSK. Read More

What are the main diagnostic segments in the US chronic idiopathic-constipation market?

Main diagnostic segments include blood tests, sigmoidoscopy, colonoscopy, and others, with colonoscopy valued at $205.66 Million in 2024. Read More

What treatment options are available in the US chronic idiopathic-constipation market?

Treatment options include drugs, surgery, laxatives, and antiemetics, with laxatives valued at $300.0 Million in 2024. Read More

What is the valuation of the surgery segment in the US chronic idiopathic-constipation market?

The surgery segment was valued at $100.0 Million in 2024. Read More

Which end-user industries are involved in the US chronic idiopathic-constipation market?

End-user industries include hospitals, gastroenterology clinics, and diagnostic centers, with hospitals valued at $400.0 Million in 2024. Read More

How does the market performance of diagnostic centers compare to hospitals?

Diagnostic centers were valued at $300.0 Million in 2024, which is lower than the $400.0 Million valuation of hospitals. Read More

What is the potential for growth in the US chronic idiopathic-constipation market?

The market appears to have substantial growth potential, with a projected valuation increase to $2750.67 Million by 2035. Read More

US Chronic Idiopathic Constipation Market

ID: MRFR/Pharma/17380-HCR

100 Pages

Vikita Thakur

Last Updated: April 06, 2026

US Chronic Idiopathic Constipation Market Research Report By Diagnosis (Blood Tests, Sigmoidoscopy, Colonoscopy, Balloon Expulsion Test, Anorectal Manometry), By Treatment (Drugs) and By End User (Hospitals & Clinics, Diagnostic Centers) - Growth & Industry Forecast 2025 To 2035

US Chronic Idiopathic Constipation Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Security, Access Control and Robotics, BY Diagnosis (USD Million)
  1. 4.1.1 blood tests
  2. 4.1.2 sigmoidoscopy
  3. 4.1.3 colonoscopy
  4. 4.1.4 balloon expulsion test
  5. 4.1.5 anorectal manometry
  6. 4.1.6 colonic transit study
  7. 4.1.7 defecography
  8. 4.1.8 others
2. 4.2 Security, Access Control and Robotics, BY Treatment (USD Million)
  1. 4.2.1 drugs
  2. 4.2.2 surgery
  3. 4.2.3 acid neutralizers
  4. 4.2.4 laxatives and antidiarrheal
  5. 4.2.5 antiemetics
  6. 4.2.6 antiulcer
  7. 4.2.7 lubiprostone (amitiza)
  8. 4.2.8 linaclotide (linzess)
  9. 4.2.9 misoprostol (Cytotec)
  10. 4.2.10 colchicine/probenecid (Col-Probenecid)
  11. 4.2.11 others
  12. 4.2.12 Onabotulinumtoxin A (Botox)
3. 4.3 Security, Access Control and Robotics, BY End-User Industries (USD Million)
  1. 4.3.1 hospitals
  2. 4.3.2 gastroenterology clinics
  3. 4.3.3 diagnostic centers
  4. 4.3.4 others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 AbbVie (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Boehringer Ingelheim (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Ironwood Pharmaceuticals (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Takeda Pharmaceutical (JP)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AstraZeneca (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sucampo Pharmaceuticals (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Salix Pharmaceuticals (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 GSK (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY DIAGNOSIS
3. 6.3 US MARKET ANALYSIS BY TREATMENT
4. 6.4 US MARKET ANALYSIS BY END-USER INDUSTRIES
5. 6.5 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
8. 6.8 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
9. 6.9 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
10. 6.10 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
11. 6.11 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DIAGNOSIS, 2024 (% SHARE)
12. 6.12 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
13. 6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TREATMENT, 2024 (% SHARE)
14. 6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TREATMENT, 2024 TO 2035 (USD Million)
15. 6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END-USER INDUSTRIES, 2024 (% SHARE)
16. 6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END-USER INDUSTRIES, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
  3. 7.2.3 BY END-USER INDUSTRIES, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Security, Access Control and Robotics Market Segmentation

Security, Access Control and Robotics By Diagnosis (USD Million, 2025-2035)

blood tests
sigmoidoscopy
colonoscopy
balloon expulsion test
anorectal manometry
colonic transit study
defecography
others

Security, Access Control and Robotics By Treatment (USD Million, 2025-2035)

drugs
surgery
acid neutralizers
laxatives and antidiarrheal
antiemetics
antiulcer
lubiprostone (amitiza)
linaclotide (linzess)
misoprostol (Cytotec)
colchicine/probenecid (Col-Probenecid)
others
Onabotulinumtoxin A (Botox)

Security, Access Control and Robotics By End-User Industries (USD Million, 2025-2035)

hospitals
gastroenterology clinics
diagnostic centers
others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”